A novel dengue virus inhibitor, BP13944, discovered by high-Throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 110-119

  Yang, Chi Chen ^a   Hu, Han Shu ^a   Wu, Ren Huang ^a   Wu, Szu Huei ^a   Lee, Shiow Ju ^a   Jiaang, Weir Torn ^a   Chern, Jyh Haur ^a   Huang, Zhi Shun ^b   Wu, Huey Nan ^b   Chang, Chung Ming ^a   Yueh, Andrew ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BP 13944; LUCIFERASE; PROTEINASE; UNCLASSIFIED DRUG; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN BHK; CYTOTOXICITY; DENGUE VIRUS 2; DOSE RESPONSE; DRUG POTENCY; DRUG TARGETING; HIGH THROUGHPUT SCREENING; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REPLICON; RNA PURIFICATION; RNA REPLICATION; RNA SYNTHESIS; SEQUENCE ANALYSIS; SEROTYPE; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; CRICETINAE; DENGUE VIRUS; DRUG RESISTANCE, VIRAL; REPLICON; SERINE ENDOPEPTIDASES; SMALL MOLECULE LIBRARIES; VIRUS REPLICATION;

EID: 84891551118     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01281-13     Document Type: Article

References (83)

1. Gubler DJ, Kuno G, Markoff L. 2007. Flaviviruses, p 1153-1253. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Ye J, Zhu B, Fu ZF, Chen H, Cao S. 2012. Immune evasion strategies of flaviviruses. Vaccine 31:461-471. http://dx.doi.org/10.1016/j.vaccine.2012.11. 015.
3. World Health Organization. 2012. Dengue and severe dengue. World Health Organization, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/ fs117/en/.
4. World Health Organization. 2009. Dengue: guidelines for diagnosis, treatment, prevention and control. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2009/9789241547871-eng.pdf.
5. Halstead SB. 1980. Dengue haemorrhagic fever - a public health problem and a field for research. Bull. World Health Organ. 58:1-21.
6. Gubler DJ. 1989. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: Top down or bottom up. Charles Franklin Craig lecture. Am. J. Trop. Med. Hyg. 40:571-578.
7. Pinheiro FP. 1989. Dengue in the Americas. 1980-1987. Epidemiol. Bull. 10:1-8.
8. Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, Wang QY, Shi PY. 2010. Strategies for development of dengue virus inhibitors. Antiviral Res. 85:450-462. http://dx.doi.org/10.1016/j.antiviral.2009.12.011.
9. Simmons CP, Farrar JJ, Nguyen v V, Wills B. 2012. Dengue. N. Engl. J. Med. 366:1423-1432. http://dx.doi.org/10.1056/NEJMra1110265.
10. Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH. 1985. Nucleotide sequence of yellow fever virus: Implications for flavivirus gene expression and evolution. Science 229:726-733. http://dx.doi.org/10.1126/ science.4023707.
11. Chambers TJ, Hahn CS, Galler R, Rice CM. 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:649- 688. http://dx.doi.org/10.1146/annurev.mi.44.100190.003245.
12. Falgout B, Pethel M, Zhang YM, Lai CJ. 1991. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 65:2467-2475.
13. Kummerer BM, Rice CM. 2002. Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J. Virol. 76:4773-4784. http://dx.doi.org/10.1128/JVI.76 .10.4773-4784.2002.
14. Liu WJ, Chen HB, Khromykh AA. 2003. Molecular and functional analyses of Kunjin virus infectious cDNA clones demonstrate the essential roles for NS2A in virus assembly and for a nonconservative residue in NS3 in RNA replication. J. Virol. 77:7804-7813. http://dx.doi.org/10.1128/JVI.77.14.7804-7813.2003.
15. Patkar CG, Kuhn RJ. 2008. Yellow fever virus NS3 plays an essential role in virus assembly independent of its known enzymatic functions. J. Virol.82:3342-3352. http://dx.doi.org/10.1128/JVI.02447-07.
16. Best SM, Morris KL, Shannon JG, Robertson SJ, Mitzel DN, Park GS, Boer E, Wolfinbarger JB, Bloom ME. 2005. Inhibition of interferonstimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J. Virol. 79:12828-12839. http://dx.doi.org/10.1128/JVI.79.20.12828- 12839.2005.
17. Guo JT, Hayashi J, Seeger C. 2005. West Nile virus inhibits the signal transduction pathway of alpha interferon. J. Virol. 79:1343-1350. http://dx.doi.org/10.1128/JVI.79.3.1343-1350.2005.
18. Liu WJ, Wang XJ, Mokhonov VV, Shi PY, Randall R, Khromykh AA. 2005. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J. Virol. 79:1934-1942. http://dx.doi.org/10.1128/JVI. 79.3.1934-1942.2005.
19. Munoz-Jordan JL, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin WI, Garcia-Sastre A. 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79:8004- 8013. http://dx.doi.org/10.1128/JVI.79.13.8004-8013.2005.
20. Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A. 2003. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. U. S. A. 100:14333-14338. http://dx.doi.org/10.1073/pnas.2335168100.
21. Wengler G, Wengler G. 1991. The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology 184:707-715. http://dx.doi.org/10.1016/0042-6822(91)90440-M.
22. Falgout B, Miller RH, Lai CJ. 1993. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: Identification of a domain required for NS2B-NS3 protease activity. J. Virol. 67:2034-2042.
23. Wengler G, Wengler G. 1993. The NS3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology 197:265-273. http://dx.doi.org/10.1006/viro.1993.1587.
24. Bazan JF, Fletterick RJ. 1989. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology 171:637-639. http://dx.doi.org/10.1016/0042-6822(89)90639-9.
25. Gorbalenya AE, Donchenko AP, Koonin EV, Blinov VM. 1989. N-terminal domains of putative helicases of flavi- and pestiviruses may be serine proteases. Nucleic Acids Res. 17:3889-3897. http://dx.doi.org/10.1093/nar/17.10. 3889.
26. Valle RP, Falgout B. 1998. Mutagenesis of the NS3 protease of dengue virus type 2. J. Virol. 72:624-632.
27. Xu T, Sampath A, Chao A, Wen D, Nanao M, Chene P, Vasudevan SG, Lescar J. 2005. Structure of the dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 A. J. Virol. 79:10278-10288. http://dx.doi.org/10.1128/JVI.79.16.10278-10288.2005.
28. Luo D, Xu T, Hunke C, Gruber G, Vasudevan SG, Lescar J. 2008. Crystal structure of the NS3 protease-helicase from dengue virus. J. Virol. 82:173-183. http://dx.doi.org/10.1128/JVI.01788-07.
29. Luo D, Wei N, Doan DN, Paradkar PN, Chong Y, Davidson AD, Kotaka M, Lescar J, Vasudevan SG. 2010. Flexibility between the proteaseand helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications. J. Biol. Chem. 285: 18817-18827. http://dx.doi.org/10. 1074/jbc.M109.090936.
30. Menendez-Arias L. 2010. Molecular basis of human immunodeficiency virus drug resistance: An update. Antiviral Res. 85:210-231. http://dx.doi.org/10. 1016/j.antiviral.2009.07.006.
31. Venkatraman S. 2012. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections. Trends Pharmacol. Sci. 33:289-294. http://dx.doi.org/10.1016/j.tips.2012.03.012.
32. Casey LC, Lee WM. 2013. Hepatitis C virus therapy update 2013. Curr. Opin. Gastroenterol. 29:243-249. http://dx.doi.org/10.1097/MOG.0b013e32835ff972.
33. Marks KM, Jacobson IM. 2012. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. Antivir. Ther. 17:1119-1131. http://dx.doi.org/10. 3851/IMP2424.
34. Noble CG, Shi PY. 2012. Structural biology of dengue virus enzymes: Towards rational design of therapeutics. Antiviral Res. 96:115-126. http://dx.doi.org/10.1016/j.antiviral.2012.09.007.
35. Sampath A, Padmanabhan R. 2009. Molecular targets for flavivirus drug discovery. Antiviral Res. 81:6-15. http://dx.doi.org/10.1016/j.antiviral.2008. 08.004.
36. Lescar J, Luo D, Xu T, Sampath A, Lim SP, Canard B, Vasudevan SG. 2008. Towards the design of antiviral inhibitors against flaviviruses: The case for the multifunctional NS3 protein from dengue virus as a target. Antiviral Res. 80:94-101. http://dx.doi.org/10.1016/j.antiviral.2008.07.001
37. Bollati M, Alvarez K, Assenberg R, Baronti C, Canard B, Cook S, Coutard B, Decroly E, de Lamballerie X, Gould EA, Grard G, Grimes JM, Hilgenfeld R, Jansson AM, Malet H, Mancini EJ, Mastrangelo E, Mattevi A, Milani M, Moureau G, Neyts J, Owens RJ, Ren J, Selisko B, Speroni S, Steuber H, Stuart DI, Unge T, Bolognesi M. 2010. Structure and functionality in flavivirus NS-proteins: Perspectives for drug design. Antiviral Res. 87:125-148. http://dx.doi.org/10. 1016/j.antiviral.2009.11.009.
38. Leung D, Schroder K, White H, Fang NX, Stoermer MJ, Abbenante G, Martin JL, Young PR, Fairlie DP. 2001. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J. Biol. Chem. 276:45762-45771. http://dx.doi.org/ 10.1074/jbc.M107360200.
39. Yang CC, Hsieh YC, Lee SJ, Wu SH, Liao CL, Tsao CH, Chao YS, Chern JH, Wu CP, Yueh A. 2011. Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay. Antimicrob. Agents Chemother. 55:229-238. http://dx.doi.org/10.1128/AAC.00855-10.
40. Deng J, Li N, Liu H, Zuo Z, Liew OW, Xu W, Chen G, Tong X, Tang W, Zhu J, Zuo J, Jiang H, Yang CG, Li J, Zhu W. 2012. Discovery of novel small molecule inhibitors of dengue viral NS2B-NS3 protease using virtual screening and scaffold hopping. J. Med. Chem. 55:6278-6293. http://dx.doi.org/10.1021/ jm300146f.
41. Xu S, Li H, Shao X, Fan C, Ericksen B, Liu J, Chi C, Wang C. 2012. Critical effect of peptide cyclization on the potency of peptide inhibitorsagainst dengue virus NS2B-NS3 protease. J. Med. Chem. 55:6881-6887.http://dx.doi.org/10.1021/jm300655h.
42. Rothan HA, Han HC, Ramasamy TS, Othman S, Rahman NA, Yusof R.2012. Inhibition of dengue NS2B-NS3 protease and viral replication inVero cells by recombinant retrocyclin-1. BMC Infect. Dis. 12:314. http://dx.doi.org/10.1186/ 1471-2334-12-314.
43. Chanprapaph S, Saparpakorn P, Sangma C, Niyomrattanakit P, Hannongbua S, Angsuthanasombat C, Katzenmeier G. 2005. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem. Biophys. Res. Commun. 330:1237-1246. http://dx.doi.org/10.1016/j.bbrc.2005.03.107.
44. Ganesh VK, Muller N, Judge K, Luan CH, Padmanabhan R, Murthy KH. 2005. Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg. Med. Chem. 13:257-264. http://dx.doi.org/10.1016/j.bmc.2004.09.036.
45. Kiat TS, Pippen R, Yusof R, Ibrahim H, Khalid N, Rahman NA. 2006. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Bioorg. Med. Chem. Lett. 16:3337-3340. http://dx.doi.org/10.1016/j.bmcl.2005.12. 075.
46. Yin Z, Patel SJ, Wang WL, Wang G, Chan WL, Rao KR, Alam J, Jeyaraj DA, Ngew X, Patel V, Beer D, Lim SP, Vasudevan SG, Keller TH. 2006. Peptide inhibitors of dengue virus NS3 protease. Part 1: Warhead. Bioorg. Med. Chem. Lett. 16:36-39. http://dx.doi.org/10.1016/j.bmcl.2005.09.062.
47. Yin Z, Patel SJ, Wang WL, Chan WL, Ranga Rao KR, Wang G, Ngew X, Patel V, Beer D, Knox JE, Ma NL, Ehrhardt C, Lim SP, Vasudevan SG, Keller TH. 2006. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg. Med. Chem. Lett. 16:40-43. http://dx.doi.org/10.1016/j.bmcl.2005.09.049.
48. Bodenreider C, Beer D, Keller TH, Sonntag S, Wen D, Yap L, Yau YH,Shochat SG, Huang D, Zhou T, Caflisch A, Su XC, Ozawa K, Otting G, Vasudevan SG, Lescar J, Lim SP. 2009. A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Anal. Biochem. 395:195-204. http://dx.doi.org/10.1016/j.ab.2009.08.013.
49. Tomlinson SM, Malmstrom RD, Russo A, Mueller N, Pang YP, Watowich SJ. 2009. Structure-based discovery of dengue virus protease inhibitors. Antiviral Res. 82:110-114. http://dx.doi.org/10.1016/j.antiviral.2009.02.190.
50. Byrd CM, Grosenbach DW, Berhanu A, Dai D, Jones KF, Cardwell KB, Schneider C, Yang G, Tyavanagimatt S, Harver C, Wineinger KA, Page J, Stavale E, Stone MA, Fuller KP, Lovejoy C, Leeds JM, Hruby DE,Jordan R. 2013. Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase. Antimicrob. Agents Chemother. 57:1902- 1912. http://dx.doi.org/10.1128/AAC. 02251-12.
51. Yu W, Gill T, Wang L, Du Y, Ye H, Qu X, Guo JT, Cuconati A, Zhao K, Block TM, Xu X, Chang J. 2012. Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection. J. Med. Chem. 55:6061-6075. http://dx.doi.org/10.1021/jm300171v.
52. Chao B, Tong XK, Tang W, Li DW, He PL, Garcia JM, Zeng LM, Gao AH, Yang L, Li J, Nan FJ, Jacobs M, Altmeyer R, Zuo JP, Hu YH. 2012. Discovery and optimization of 2,4-diaminoquinazoline derivatives as a new class of potent dengue virus inhibitors. J. Med. Chem. 55:3135-3143. http://dx.doi.org/10.1021/ jm2015952.
53. Jones CT, Patkar CG, Kuhn RJ. 2005. Construction and applications of yellow fever virus replicons. Virology 331:247-259. http://dx.doi.org/10.1016/j. virol.2004.10.034.
54. Horscroft N, Lai VC, Cheney W, Yao N, Wu JZ, Hong Z, Zhong W. 2005. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Antivir. Chem. Chemother. 16:1-12.
55. Rice CM. 2011. New insights into HCV replication: Potential antiviral targets. Top. Antivir. Med. 19:117-120.
56. Tariq H, Manzoor S, Parvaiz F, Javed F, Fatima K, Qadri I. 2012. An overview: In vitro models of HCV replication in different cell cultures. Infect. Genet. Evol. 12:13-20. http://dx.doi.org/10.1016/j.meegid.2011.10.009.
57. Yang PL, Gao M, Lin K, Liu Q, Villareal VA. 2011. Anti-HCV drugs in the pipeline. Curr. Opin. Virol. 1:607-616. http://dx.doi.org/10.1016/j.coviro.2011. 10.019.
58. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, II, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100. http://dx.doi.org/10.1038/nature08960.
59. Einav S, Sobol HD, Gehrig E, Glenn JS. 2010. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J. Infect. Dis. 202:65-74. http://dx.doi.org/10.1086/653080.
60. Pang X, Zhang M, Dayton AI. 2001. Development of dengue virus type 2 replicons capable of prolonged expression in host cells. BMC Microbiol. 1:18. http://dx.doi.org/10.1186/1471-2180-1-18.
61. Puig-Basagoiti F, Tilgner M, Forshey BM, Philpott SM, Espina NG, Wentworth DE, Goebel SJ, Masters PS, Falgout B, Ren P, Ferguson DM, Shi PY. 2006. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 50:1320-1329. http://dx.doi.org/10.1128/AAC.50.4. 1320-1329.2006.
62. Ng CY, Gu F, Phong WY, Chen YL, Lim SP, Davidson A, Vasudevan SG. 2007. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res. 76:222-231. http://dx.doi.org/10.1016/j.antiviral.2007.06.007.
63. Masse N, Davidson A, Ferron F, Alvarez K, Jacobs M, Romette JL, Canard B, Guillemot JC. 2010. Dengue virus replicons: Production of an interserotypic chimera and cell lines from different species, and establishment of a cell-based fluorescent assay to screen inhibitors, validated by the evaluation of ribavirin's activity. Antiviral Res. 86:296-305. http://dx.doi.org/10.1016/j. antiviral.2010.03.010.
64. Qing M, Liu W, Yuan Z, Gu F, Shi PY. 2010. A high-throughput assay using dengue-1 virus-like particles for drug discovery. Antiviral Res. 86: 163-171. http://dx.doi.org/10.1016/j.antiviral.2010.02.313.
65. Shum D, Smith JL, Hirsch AJ, Bhinder B, Radu C, Stein DA, Nelson JA, Fruh K, Djaballah H. 2010. High-content assay to identify inhibitors of dengue virus infection. Assay Drug Dev. Tech. 8:553-570. http://dx.doi.org/10.1089/adt.2010. 0321.
66. Xie X, Wang QY, Xu HY, Qing M, Kramer L, Yuan Z, Shi PY. 2011. Inhibition of dengue virus by targeting viral NS4B protein. J. Virol. 85: 11183-11195. http://dx.doi.org/10.1128/JVI.05468-11.
67. Hsu YC, Chen NC, Chen PC, Wang CC, Cheng WC, Wu HN. 2012. Identification of a small-molecule inhibitor of dengue virus using a replicon system. Arch. Virol. 157:681-688. http://dx.doi.org/10.1007/s00705-012-1224-z.
68. Stevens AJ, Gahan ME, Mahalingam S, Keller PA. 2009. The medicinal chemistry of dengue fever. J. Med. Chem. 52:7911-7926. http://dx.doi.org /10.1021/jm900652e.
69. Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, Ma SH, Huang YY, Huang YL, Kao CL, King CC. 1998. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J. Virol. 72:9729-9737.
70. Chen LK, Lin YL, Liao CL, Lin CG, Huang YL, Yeh CT, Lai SC, Jan JT, Chin C. 1996. Generation and characterization of organ-tropism mutants of Japanese encephalitis virus in vivo and in vitro. Virology 223:79-88. http://dx.doi.org/10.1006/viro.1996.0457.
71. Miroux B, Walker JE. 1996. Over-production of proteins in Escherichia coli: Mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J. Mol. Biol. 260:289-298. http://dx.doi.org/10.1006/ jmbi.1996.0399.
72. Burke D. 2000. Methods in yeast genetics: A Cold Spring Harbor Laboratory course manual, 2000 ed. Cold Spring Harbor Laboratory Press, Plainview, NY.
73. Yang CC, Tsai MH, Hu HS, Pu SY, Wu RH, Wu SH, Lin HM, Song JS, Chao YS, Yueh A. 2013. Characterization of an efficient dengue virus replicon for development of assays of discovery of small molecules against dengue virus. Antiviral Res. 98:228-241. http://dx.doi.org/10.1016/j.antiviral.2013.03.001.
74. Lin YL, Liu CC, Lei HY, Yeh TM, Lin YS, Chen RM, Liu HS. 2000. Infection of five human liver cell lines by dengue-2 virus. J. Med. Virol. 60:425-431. http://dx.doi.org/10.1002/(SICI)1096-9071(200004)60:4-425::AID-JMV10-3.0.CO;2-A.
75. Wu SF, Lee CJ, Liao CL, Dwek RA, Zitzmann N, Lin YL. 2002. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76: 3596-3604. http://dx.doi.org/10.1128/JVI.76.8.3596-3604.2002.
76. Houng HH, Hritz D, Kanesa-thasan, N. 2000. Quantitative detection of dengue 2 virus using fluorogenic RT-PCR based on 3=-noncoding sequence. J. Virol. Methods 86:1-11. http://dx.doi.org/10.1016/S0166-0934(99)00166-4.
77. Deas TS, Binduga-Gajewska I, Tilgner M, Ren P, Stein DA, MoultonHM, Iversen PL, Kauffman EB, Kramer LD, Shi PY. 2005. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79:4599-4609. http://dx.doi.org/10.1128/JVI.79.8. 4599-4609.2005.
78. Zou G, Puig-Basagoiti F, Zhang B, Qing M, Chen L, Pankiewicz KW, Felczak K, Yuan Z, Shi PY. 2009. A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology 384:242-252. http://dx.doi.org/10.1016/j.virol.2008.11.003.
79. Pu SY, Wu RH, Yang CC, Jao TM, Tsai MH, Wang JC, Lin HM, Chao YS, Yueh A. 2011. Successful propagation of flavivirus infectious cDNAs by a novel method to reduce the cryptic bacterial promoter activity of virus genomes. J. Virol. 85:2927-2941. http://dx.doi.org/10.1128/JVI.01986-10.
80. Palmer M, Chan A, Dieckmann T, Honek J. 2012. Biochemical pharmacology, 1st ed. John Wiley & Sons, Hoboken, NJ.
81. Beran RK, Pyle AM. 2008. Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J. Biol. Chem. 283:29929-29937. http://dx.doi.org/10.1074/jbc.M804065200.
82. Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. 1999. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7:1353- 1363. http://dx.doi.org/10.1016/S0969-2126(00)80025-8.
83. Wang CC, Huang ZS, Chiang PL, Chen CT, Wu HN. 2009. Analysis of the nucleoside triphosphatase,RNA triphosphatase, and unwinding activities of the helicase domain of dengue virus NS3 protein. FEBS Lett. 583: 691-696. http://dx.doi.org/10.1016/j.febslet.2009.01.008.